Vigil Neuroscience, Inc., (VIGL): Price and Financial Metrics
VIGL Price/Volume Stats
| Current price | $6.64 | 52-week high | $16.77 |
| Prev. close | $5.99 | 52-week low | $4.68 |
| Day low | $5.84 | Volume | 4,873 |
| Day high | $6.64 | Avg. volume | 46,451 |
| 50-day MA | $6.44 | Dividend yield | N/A |
| 200-day MA | $9.44 | Market Cap | 238.20M |
VIGL Stock Price Chart Interactive Chart >
Vigil Neuroscience, Inc., (VIGL) Company Bio
Vigil Neuroscience, Inc., a biotechnology company, discovers and develops novel therapeutics that take advantage of breakthroughs in science and human genetics of microglia. It harnesses the power of microglia for the treatment of neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. The company was incorporated in 2020 and is based in Cambridge, Massachusetts.
Latest VIGL News From Around the Web
Below are the latest news stories about VIGIL NEUROSCIENCE INC that investors may wish to consider to help them evaluate VIGL as an investment opportunity.
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting- Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg - - On track to report 6-month interim data from IGNITE trial in Q4 2023 from first 6 patients who have received 20 mg/kg of VGL101 - WATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia f |
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer’s Disease - - IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed to proceed with partial clinical hold related to maximum exposure limit – - Phase 1 dosing expected to commence in October 2023; No anticipated delays in current clinical development plans -- Company to host virtual R&D event highlighting its small molecule TREM2 agonist program on September 13, 2023 |
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare ConferenceWATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of the management team will participate in a fireside chat at the 2023 Morgan Stanley Global Healthcare Conference in New York City on Monday, September 11, 2023, at 9:20 a.m. ET. To access the live event, please click here to register for th |
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 - - Small molecule TREM2 agonist IND submission and initiation of Phase 1 clinical trial on track for fourth quarter of 2023 - - Appoints drug development veteran Christopher J. Silber, M.D. as Chief Medical Officer - WATERTOWN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed |
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical OfficerWATERTOWN, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Christopher J. Silber, M.D. as Chief Medical Officer. Dr. Silber brings over 30 years of biopharmaceutical industry experience and a track record of clinical and regulatory success developing novel therapeutics in neuroscience. “We are t |
VIGL Price Returns
| 1-mo | 15.38% |
| 3-mo | -29.74% |
| 6-mo | -33.53% |
| 1-year | -26.22% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -46.88% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...